Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Entera Bio (ENTX) Equity Average (2019 - 2025)

Entera Bio has reported Equity Average over the past 7 years, most recently at $14.2 million for Q4 2025.

  • For the quarter ending Q4 2025, Equity Average rose 94.98% year-over-year to $14.2 million, compared with a TTM value of $14.2 million through Dec 2025, up 94.98%, and an annual FY2025 reading of $10.6 million, up 14.7% over the prior year.
  • Equity Average came in at $14.2 million for Q4 2025, down from $16.2 million in the prior quarter.
  • In the past five years, Equity Average ranged from a high of $26.3 million in Q3 2021 to a low of $7.2 million in Q3 2023.
  • Median Equity Average over the past 5 years was $13.4 million (2022), compared with a mean of $14.1 million.
  • The sharpest move saw Equity Average surged 305.22% in 2021, then plummeted 54.19% in 2023.
  • Over 5 years, Equity Average stood at $24.4 million in 2021, then tumbled by 46.63% to $13.0 million in 2022, then crashed by 36.23% to $8.3 million in 2023, then decreased by 12.57% to $7.3 million in 2024, then skyrocketed by 94.98% to $14.2 million in 2025.
  • Per Business Quant, the three most recent readings for ENTX's Equity Average are $14.2 million (Q4 2025), $16.2 million (Q3 2025), and $18.3 million (Q2 2025).